Pfizer (NYSE:PFE) yesterday closed its $15 billion acquisition of Hospira, its largest-ever buyout, expanding its portfolio of generic injectable drugs and copies of biotech medicines. Hospira makes generic versions of injectable drugs used in hospitals, pumps to deliver such medicine and also sells biosimilars or copies of biotech drugs. Pfizer paid $90 per share in cash, a 39% […]
Pfizer
FTC clears Pfizer’s $15B Hospira buy
Pfizer (NYSE:PFE) said Monday it won approval from the Federal Trade Commission for its $15 billion acquisition of Hospira (NYSE:HSP). The clearance came with a caveat –Pfizer must divest itself of its Acetylcysteine, Clindamycin, Voriconazole and Melphalan sterile injectable assets, according to the company. The news from the FTC came August 21, according to an SEC filing from […]
Pfizer wins Canadian approval for $15B Hospira buy
Pfizer (NYSE:PFE) said it won approval from the Canadian Competition Bureau for its $15 billion acquisition of Hospira (NYSE:HSP). As part of the agreement, the healthcare and pharmaceutical giant said it committed to divesting certain assets of the company in Canada, according to a press release. “We are pleased the Canadian Competition Bureau concluded its review […]
Pfizer offers concessions to win EU okay for Hospira deal
(Reuters) — Pfizer (NYSE:PFE) offered concessions in a bid to win European Union regulatory approval for its $15 billion takeover of U.S. rival Hospira (NYSE:HSP), the European Commission said today. The EU competition authority did not provide details of Pfizer’s proposal, in line with its policy. It extended the deadline for its decision to Aug. 4 […]
U.K. OKs $2B Steris-Synergy merger | The week in medtech M&A
The Pfizer-Hospira Deal: Do Pharma and Device Companies Need Each Other?
Having been at the flag-raising ceremony for Hospira when it spun out of Abbott back in 2004, the news of Pfizer’s acquisition was a bit emotional for me. I didn’t cry or anything, but I did feel a little sad, and a little proud, and maybe a little hopeful at the end of the day.
Pfizer offers $15 billion for Hospira
Lack of FDA approval is no longer a deal-breaker for a big exit | The week in medtech M&A
Baxter sheds vaccines biz for $635M
Insurer escapes Stryker lawsuit over Duracon Uni-Knees
EpiPen makers fined $625k over ‘deceptive’ TV ad | MassDevice.com On Call
MASSDEVICE ON CALL — EpiPen providers Pfizer (NYSE:PFE) and Mylan Specialty agreed to a $625,000 settlement to close the books on charges that they misled consumers about the efficacy of the emergency allergy medication dispenser.
The companies in April aired a television commercial, and ran a parallel print ad, that showed a mother and her son discussing the EpiPen system on the way to a birthday party.